Outlook Therapeutics Inc [OTLK] stock prices are up 0.96% to $1.05 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OTLK shares have gain 11.03% over the last week, with a monthly amount drifted -56.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on August 29, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Guggenheim downgraded its rating to Neutral on August 28, 2025. On December 02, 2024, downgrade downgraded it’s rating to Neutral. BTIG Research upgraded its rating to a Buy but stick to its price target of $50 on March 27, 2024. Chardan Capital Markets upgraded its rating to a Buy but $3 remained the price target by the analyst firm on February 15, 2024. Guggenheim upgraded its rating to Buy for this stock on January 25, 2024. In a note dated December 27, 2023, CapitalOne upgraded an Overweight rating on this stock but restated the target price of $5.
The stock price of Outlook Therapeutics Inc [OTLK] has been fluctuating between $0.79 and $6.98 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $1.05 at the most recent close of the market. An investor can expect a potential drop of -4.76% based on the average OTLK price forecast.
Analyzing the OTLK fundamentals
Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -43.35%, Pretax Profit Margin comes in at -25.93%, and Net Profit Margin reading is -25.93%. To continue investigating profitability, this company’s Return on Assets is posted at -1.94, Equity is 0.9 and Total Capital is 7.98. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Outlook Therapeutics Inc [NASDAQ:OTLK]’s Current Ratio is 0.67. Further, the Quick Ratio stands at 0.54, while the Cash Ratio is 0.28. Considering the valuation of this stock, the price to sales ratio is 30.89.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased.
